Immune complex membranoproliferative glomerulonephritis (ic-MPGN)

Clinical trials for Immune complex membranoproliferative glomerulonephritis (ic-MPGN) explained in plain language.

Never miss a new study

Get alerted when new Immune complex membranoproliferative glomerulonephritis (ic-MPGN) trials appear

Sign up with your email to follow new studies for Immune complex membranoproliferative glomerulonephritis (ic-MPGN), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1 Not yet finished but already full! 2 Completed 2

Can a targeted therapy tame rare kidney diseases in daily practice?

Disease control Recruiting now

This study looks at how well the medication pegcetacoplan works and how safe it is for people with two rare kidney conditions: C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). Researchers will follow about 150 patients who are…

Matched conditions: IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)

Phase 4 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control

Last updated Sep 11, 2026 00:00 UTC

Immune complex membranoproliferative glomerulonephritis (ic-MPGN)

Get alerted when new Immune complex membranoproliferative glomerulonephritis (ic-MPGN) trials appear

Can a targeted therapy tame rare kidney diseases in daily practice?